8-K Announcements
6Material company update
Apr 15, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Mar 17, 2026·SEC
Mainz Biomed B.V.(MYNZ)Earnings, Financials & Key Ratios
MYNZ•NASDAQ
$3.59
Price updated Jun 20, 2026
AboutMainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.Show more
- Revenue$894K-0.2%
- EBITDA-$18M+31.0%
- Net Income-$22M+17.7%
- EPS (Diluted)-22.36-1280.2%
- Gross Margin64.31%+13.0%
- EBITDA Margin-1977.47%+30.9%
- Operating Margin-2091.23%+29.7%
- Net Margin-2421.8%+17.5%
- ROE-465.82%-53.6%
MYNZ Price & Volume
Mainz Biomed B.V. (MYNZ) stock price & volume — 10-year historical chart
Loading chart...
Mainz Biomed Faces Persistent Structural Cash Burn
Investment Thesis • Updated 2024Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital exhaustion and dilution
Key Thesis Takeaways
- Mainz Biomed continues to struggle with a volatile commercial trajectory, evidenced by erratic revenue growth and an inability to achieve operational leverage despite a decentralized diagnostic model.
- The company's reliance on equity-based financing to offset significant net losses, which reached $10.6 million in 2024Q4, creates substantial dilution risk for shareholders.
- Investors should remain cautious as the firm's $91.0 million accumulated deficit and high operating expense structure suggest a long path toward sustainable profitability.
Verdict Logic
the company's reliance on external financing is underscored by a $91.0 million accumulated deficit and a consistent inability to generate positive free cash flow, which totaled -$9.1 million in 2024Q4.
MYNZ Growth Metrics
Mainz Biomed B.V. (MYNZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years26.01%
3 Years15.69%
TTM45.31%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1156.11%
Return on Capital
10 Years-331.67%
5 Years-326.05%
3 Years-244.12%
Last Year-277.78%
Peers Comparison
Key metrics vs top competitors for Mainz Biomed B.V. (MYNZ)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.59 | $3.48M | -0.16 | -0.17% | -2421.8% | -465.82% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $137.57 | $8.05B | -41.94 | 32.33% | -34.34% | -26.46% | — | |
| $276.27 | $39.57B | -181.76 | 35.9% | -9.05% | -15.13% | — | |
| $16.39 | $1.22B | -11.62 | 23.29% | -40.6% | -30.85% | — | |
| $170.77 | $22.64B | -51.44 | 32.88% | -40.1% | — | — |
Compare MYNZ vs Peers
Mainz Biomed B.V. (MYNZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MYNZ SEC Filings & Documents
Mainz Biomed B.V. (MYNZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
10-K Annual Reports
1FY 2026
Mar 31, 2026·SEC
Get notified when MYNZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MYNZ Frequently Asked Questions
Mainz Biomed B.V. (MYNZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Mainz Biomed B.V.'s revenue?
Mainz Biomed B.V. (MYNZ) reported $1.6M in revenue for fiscal year 2024. This represents a 472% increase from $0.3M in 2019.
How fast is Mainz Biomed B.V. growing?
Mainz Biomed B.V. (MYNZ) saw revenue decline by 0.2% over the past year.
Is MYNZ profitable?
Mainz Biomed B.V. (MYNZ) reported a net loss of $40.1M for fiscal year 2024.
Dividend & Returns
What is MYNZ's return on equity?
Mainz Biomed B.V. (MYNZ) has a return on equity (ROE) of -465.8%. Negative ROE indicates the company is unprofitable.
What is Mainz Biomed B.V.'s free cash flow?
Mainz Biomed B.V. (MYNZ) had negative free cash flow of $27.5M in fiscal year 2024, likely due to heavy capital investments.